{"entity":{"id":"nct07499674","kind":"trial","name":"Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung","aka":[],"tldr":"A phase 3 trial of Abenacianine in advanced solid tumours, run by Vergent Bioscience, Inc., now recruiting.","summary":"Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung is a phase 3 interventional study registered as NCT07499674 by Vergent Bioscience, Inc., with 132 participants planned, started 2026-03-31 and due to reach its primary completion in 2026-12. Interventions recorded: Abenacianine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07499674","url":"https://clinicaltrials.gov/study/NCT07499674"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["vergent-bioscience"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07499674","phase":"3","setting":"A Phase 3, Multi-center, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Abenacianine (VGT-309), a Tumor-Targeted, Activatable Fluorescent Imaging Agent, to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung - VISUALIZE 2","sponsor":"Vergent Bioscience, Inc.","enrolled":132,"outcomes":[]},"route":"/trials/nct07499674/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"vergent-bioscience","kind":"company","name":"Vergent Bioscience","route":"/companies/vergent-bioscience/"}]}}